Short answer
RECURSION PHARMACEUTICALS, INC. (RXRX) filed an 8-K current report with the SEC on November 2, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item EX-99.3 (Exhibit EX-99.3), Item 2.02 (Results of Operations and Financial Condition), Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.4 (Exhibit EX-99.4). Q3 2026 results announcement for the quarter ended September 30, 2026.
RECURSION PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 results announcement for the quarter ended September 30, 2026
- Financial details and operating results contained in Exhibit 99.1 press release
Item 5.02 · Departure/Election of Directors or Officers
- Fred Hassan appointed Board Chair and Class II director, effective October 31, 2026
- Board expanded from 9 to 10 members, signaling added leadership capacity and governance oversight
- Initial director term extends through the 2029 Annual Meeting of Stockholders
- Non-employee director compensation includes cash and equity under the existing Outside Director Compensation Policy
- No disclosed related-party transactions or selection arrangements, reducing immediate governance concerns
Item 7.01 · Regulation FD Disclosure
- Press release announces Hassan’s appointment as Board Chair, indicating a leadership transition with potential governance and strategic implications
- CGA-IGC conference data release provides new clinical or research updates, potentially affecting pipeline valuation and investor expectations
- Earnings-call presentation accompanies the November 3, 2026 investor briefing, with financial and operating details in Exhibit 99.4
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $18.6M, up from $5.2M, driven by a $10.0M Sanofi milestone payment
- Cash $561.5M at September 30, rising to approximately $748.7M pro forma after the October offering, extending runway into 2029
- REC-4881 Phase 2 data: 87% response rate, 47% median polyp reduction, with 85% remaining below baseline after treatment ended
- REC-1245 showed 2 confirmed partial responses and 91.7% disease control at doses of at least 45 mg
- Sanofi optioned an immunology candidate, triggering $10M and bringing collaboration payments to $144M, with Phase 1 expected in 2027
Item EX-99.2 · Exhibit EX-99.2
- Fred Hassan appointed Board Chair effective October 31, 2026
- Veteran pharmaceutical operator brings experience advancing medicines through development, approval and commercial launch
- Rob Hershberg remains on the Board, preserving physician-scientist and biotech leadership continuity
- Leadership change signals stronger commercialization and portfolio-execution focus as Recursion advances clinical-stage programs
Item EX-99.3 · Exhibit EX-99.3
- Phase 2 TUPELO data strengthen REC-4881’s efficacy case: 87% of patients reduced total polyp burden, with a 47% median reduction after 12 weeks
- Durability supports potential intermittent dosing: 85% remained below baseline 12 weeks after treatment stopped
- Activity spans upper and lower GI disease, including 55% median upper-GI and 50% median lower-GI reductions
- Larger, higher-risk polyps declined materially: 4 of 8 patients achieved reductions of at least 80%
- Registrational trial targeted for second half of 2027, pending FDA discussions; limited single-arm sample and safety remain key risks
Item EX-99.4 · Exhibit EX-99.4
- Sanofi optioned a potential first-in-class oral immunology candidate, triggering a $10M milestone and validating Recursion’s AI-enabled discovery platform
- Recursion received $144M in cumulative Sanofi upfront and milestone payments, with potential for more than $300M additional milestones and double-digit royalties
- Candidate expected to enter Phase 1 in 2027, with Sanofi funding and leading further development and commercialization
- REC-4881 showed 87% of evaluable FAP patients with reduced polyp burden, including a 47% median reduction after 12 weeks
- October 2026 financing supports expected cash runway into 2029, with 2026 cash operating expense guidance below $375M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other RECURSION PHARMACEUTICALS, INC. 8-K filings
Get the next RXRX 8-K as it lands
Follow RXRX for push alerts, or ask the research agent what this filing means.